VAPTOLVA is the oral Selective Vasopressin V2-Receptor Antagonist. First disease-specific therapy for ADPKD. USFDA has approved TOLVAPTAN for the treatment of ADPKD and euvolemic, hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion.
VAPTOLVA
COMPOSITION:
Tolvaptan Tablets
MODE OF ACTION:
TOLVAPTAN contains vasopressin-2-receptor antagonist, which inhibits the vasopressin-2-receptors in the kidneys and regulates the level of water and sodium in the body. The drug also reduces the development and growth of kidney cysts.
INDICATIONS
• Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ADPKD is a genetic disease characterised by the development of multiple, non-malignant cysts in kidneys, which leads to complications including chronic and acute pain, hypertension and kidney failure.)
• Tolvaptan is used to treat hyponatremia (low levels of sodium in the blood) in people with heart failure, liver disease, and syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan improves urine flow without causing the body to lose too much sodium in urine.
DOSAGE
Initiate at 45 mg (morning) plus 15 mg (evening) daily.
Titrate every 1–4 weeks to 90 mg (morning) plus 30 mg (evening) daily or maximum tolerated dose.
STORAGE
Store at room temperature not exceeding 30ᵒC.
DISCLAIMER
This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.*Images/Pack are for representation purpose only.